Show simple item record

dc.contributor.authorO'Hara, Jamie
dc.contributor.authorNeumann, Peter J.
dc.date.accessioned2022-05-05T01:01:05Z
dc.date.available2022-05-05T01:01:05Z
dc.date.issued2022-01-25
dc.identifierdoi: 10.1111/hae.14413
dc.identifier.citationO'Hara, J., & Neumann, P. J. (2022). Health technology assessment for gene therapies in haemophilia. Haemophilia, 28(S2), 19-26. https://doi.org/10.1111/hae.14413
dc.identifier.issn1351-8216
dc.identifier.doi10.1111/hae.14413
dc.identifier.urihttp://hdl.handle.net/10034/626843
dc.descriptionThis article is not available on ChesterRep
dc.publisherWiley
dc.relation.urlhttps://onlinelibrary.wiley.com/doi/10.1111/hae.14413
dc.rightsLicence for VoR version of this article starting on 2022-01-25: http://onlinelibrary.wiley.com/termsAndConditions#vor
dc.sourcepissn: 1351-8216
dc.sourceeissn: 1365-2516
dc.subjectGenetics (clinical)
dc.subjectHematology
dc.subjectGeneral Medicine
dc.titleHealth technology assessment for gene therapies in haemophilia
dc.typeArticle
dc.identifier.eissn1365-2516
dc.contributor.departmentHCD Economics; University of Chester; Tufts Medical Centre, Boston
dc.identifier.journalHaemophilia
dc.date.updated2022-05-05T01:01:05Z


This item appears in the following Collection(s)

Show simple item record